SCHEMBL23927494

SCHEMBL23927494

Cc1c(F)cc(O)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.39
PTGS2 P35354 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36
ESR1 P03372 6/20 0.36
ESR2 Q92731 6/20 0.36
CYP3A4 P08684 2/20 0.32
CHRM1 P11229 1/20 0.32
ALOX15 P16050 1/20 0.32
MAOA P21397 1/20 0.32
TBXA2R P21731 1/20 0.32
ADRA1A P35348 1/20 0.32
HTR2B P41595 1/20 0.32
BACE1 P56817 1/20 0.32
AKR1B1 P15121 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL373421 0.82 ALOX5 (0.46) ALOX5PTGS2ALDH1A1CA1ESR1
SCHEMBL881046 0.82 ALDH1A1 (0.45) HDAC1HDAC6TAAR1ALDH1A1CA12
SCHEMBL31248929 0.75 TAAR1 (0.39) ALOX5PTGS2TAAR1CA12CA1
SCHEMBL4602927 0.75 AGTR1 (0.40) HDAC1HDAC6ALDH1A1
SCHEMBL28872076 0.75 CYP3A4 (0.38) HDAC1HDAC6ALDH1A1CYP3A4ALOX15
SCHEMBL14087814 0.75 ACHE (0.43) HDAC1HDAC6TAAR1ALDH1A1CA12
SCHEMBL9918977 0.75 HDAC1 (0.40) HDAC1HDAC6ALDH1A1
SCHEMBL6797282 0.75 CYP3A4 (0.46) ALOX5PTGS2ALDH1A1CA1ESR1
SCHEMBL12396449 0.75 CYP3A4 (0.46) HDAC1HDAC6TAAR1ALDH1A1CA12
SCHEMBL12689887 0.72 HDAC1 (0.37) HDAC1HDAC6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
CN-118317774-A Pharmaceutical compositions comprising quinazoline compounds 安斯泰来制药株式会社 2024-07-09 CN disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
CN-116848120-A Quinazoline compounds for inducing G12D mutant KRAS proteolysis 安斯泰来制药株式会社 2023-10-03 CN disclosed
WO-2023120742-A1 PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2023-06-29 WO disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 ALOX5 2444/4885PTGS2 3872/4885HDAC1 84/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 ALOX5 2444/4885PTGS2 3872/4885HDAC1 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.